Effect of heated tobacco products and traditional cigarettes on pulmonary toxicity and SARS-CoV-2-induced lung injury

Toxicology. 2022 Sep:479:153318. doi: 10.1016/j.tox.2022.153318. Epub 2022 Sep 9.

Abstract

Cigarette smoke (CS) significantly contributes to the development of chronic obstructive pulmonary disease (COPD). Heated tobacco products (HTPs), newly developed cigarette products, have been proposed as an alternative for safe cigarette smoking. Although it is plausible to think that replacing traditional cigarettes with HTPs would lower the risks of COPD, this notion requires confirmation by further investigations from sources independent of the tobacco industry. COPD is characterized by an ongoing inflammatory process in the lungs, and the renin-angiotensin system (RAS) has been implicated in the pathogenesis of COPD. Angiotensin-converting enzyme-2 (ACE2) functions as a negative regulator of RAS and has been suggested as a cellular receptor for the causative agent of SARS-CoV-2. It has been shown that smoking is most likely associated with the negative progression and adverse outcomes of SARS-CoV-2. In this study, we found that cigarette smoke extracts from traditional cigarettes (CSE) caused higher cytotoxicity and higher oxidative stress levels than extracts from HTPs (HTPE) in two lung cell lines (Calu-3 and Beas-2B). CSE and HTPE induced RAS activation, MAPK activation, and NF-kB inflammatory pathway activation, resulting in the production of inflammatory cytokines. Furthermore, CSE and a high dose of HTPE reduced tight junction proteins, including claudin 1, E-cadherin, and ZO-1, and disrupted lung epidermal tight junctions at the air-liquid interface (ALI). Finally, CSE and HTPE enhanced the spike protein S1-induced lung injury response. Together, these results suggest that HTPE induced similar lung pathogenesis relevant to COPD and SARS-CoV-2-induced lung injury caused by CSE.

Keywords: Air-liquid-interface (ALI); Angiotensin-converting enzyme-2 (ACE2); Heated tobacco products; Lung injury; Pulmonary toxicity; SARS-CoV-2; Spike protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • Angiotensins
  • COVID-19*
  • Cadherins
  • Claudin-1
  • Cytokines
  • Lung Diseases* / pathology
  • Lung Injury* / chemically induced
  • NF-kappa B
  • Nicotiana
  • Pulmonary Disease, Chronic Obstructive*
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • Tight Junction Proteins
  • Tobacco Products* / toxicity

Substances

  • Angiotensins
  • Cadherins
  • Claudin-1
  • Cytokines
  • NF-kappa B
  • Spike Glycoprotein, Coronavirus
  • Tight Junction Proteins
  • spike protein, SARS-CoV-2
  • Angiotensin-Converting Enzyme 2